The Myonex Solution
As part of a long-term partnership with Genethon, following the successful management of the previous Phase I/II/III study, Myonex took full operational ownership of the clinical supply execution for the pivotal trial across Europe and the United Kingdom, ensuring supply continuity, speed and control at this decisive milestone.
At the core of this model, a dedicated Myonex Project Manager acted as Genethon’s single point of contact, orchestrating all workstreams (packaging, labeling, QP release, distribution and returns) across Myonex sites. A structured governance framework, including regular status meetings, shared supply forecasting, proactive risk management and clear escalation paths, ensured that every activity was planned, aligned and executed in the right sequence.
Myonex managed the labeling and distribution of investigational and auxiliary medicinal products, as well as complex infusion kits, across multiple temperature ranges including ultra-cold handling at -80°C. Parallel blinded operations were implemented for products and matched placebo, supported by plausibility analyses to ensure visual and logistical consistency and to protect the integrity of the double-blind design.
Labeling strategies were adapted to product use and administration settings, with English-only labeling for products administered on site and multilingual booklets for products taken at home.
Distribution was organized through a dual-hub model, with Myonex Le Haillan supplying France, Spain and Belgium, and Myonex UK supplying UK sites across all required temperature conditions. Considering the high value of the investigational gene therapy product, Myonex also implemented a tightly controlled return and reallocation process under formal authorization from the French competent authority (ANSM).
From a regulatory perspective, Myonex ensured full EU QP release through its Le Haillan site in France, certifying the end-to-end supply chain, while providing QP oversight for the UK via its Leicester site.
Throughout the study, this project management backbone ensured close coordination with Genethon’s teams, including IRT-related execution support, to accelerate site readiness and secure reliable supply for patient dosing.